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Dear Editor,
The prospective randomized clinical trial of Mala-
guarnera and colleagues, published in the current issue 
of Hepatitis Monthly, investigates the potential role of a 
commercially available HMG Co-A reductase agent—ro-
suvastatin (Crestor, Astra Zeneca)—in combination with 
non-pegylated interferon and ribavirin in the treatment 
of chronic hepatitis C (HCV). HMG Co-A reductase agents, 
commonly referred to as statins, are popular agents pre-
scribed throughout the world, for their cholesterol low-
ering effects in order to reduce the risk of cardiovascular 
morbidity and mortality. They are well-recognized to im-
prove liver biochemistry in dyslipidemic patients with 
non-alcoholic fatty liver disease (1); but recent reports 
have suggested that they may possess an antiviral effect 
on HCV independent of their lipid lowering activity. In 
an in vitro study (2), various statin agents were reported 
to have differing effects on HCV replication in combina-
tion with interferon with fluvastatin (Lescol, Novartis) 
exhibiting the strongest anti-HCV activity, atorvastatin 
(Lipitor, Pfizer) had moderate activity whereas pravasta-
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tin (Pravachol, Bristol Myers Squibb) had no activity. Like-
wise, the combination of statins—specifically simvistatin 
and mevastatin—in combination with protease/poly-
merase inhibitor agents were found to clear HCV repli-
cons from culture (3). It is interesting that this in vitro 
study also found that pravastatin exhibited no antiviral 
activity (3). Clinically, the experience of statin agents in 
the treatment of HCV has not been very well-studied and 
the reported outcomes have been interesting yet at times 
conflicting. Fluvastatin monotherapy was reported to 
produce a modest 1.75 log decrease in HCV viral load in 
HCV monoinfected patients (4). The same statin, how-
ever, resulted in a paradoxical increase in viral load in a 
study of 42 HIV-HCV co-infected patients (5), presumably, 
as a result of a statin-dependent up-regulation of low 
density lipoprotein (LDL) cholesterol receptors that are 
also required for HCV entry into cells. In combination 
with peginterferon and ribavirin therapy, fluvastatin has 
been reported to be associated with an increased likeli-
hood of rapid virologic response (RVR) after 4 weeks if 
not a sustained virologic response in HIV-HCV co-infect-
ed patients (6) and a small open label single arm study 
of high viral load HCV monoinfected genotype 1 patients 
reported a suggestion of an enhanced SVR (7).
Given the lack of published randomized clinical trials 
in this area, the paper by Malaguarnera et al. is therefore 
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of interest. These investigators from the University of 
Catania, Italy, randomized 65 HCV-infected patients, the 
overwhelming majority of whom had genotype 1 infec-
tion, to receive either rosuvastatin 5 mg/day or placebo, 
in combination with non-pegylated interferon and riba-
virin. Improvements were noted in liver biochemistry, 
lipid profile, markers of insulin resistance and histology 
(steatosis and fibrosis) favoring the rosuvastatin arm. Of 
interest is the reported statistically significant advantage 
in SVR favoring the rosuvastatin arm: an apparent overall 
SVR of 69% vs. 62% in the cohort of presumably treatment 
naive and relapse patients and 51% vs. 40% in presumably 
treatment naive patients. Although these results appear 
to be impressive, restraint must be advised when inter-
preting this study. The absolute numbers of patients are 
small as the absolute difference in SVR between the two 
study arms was three patients overall and four patients 
in the treatment naive group. Moreover, the reported 
SVR with non-pegylated interferon and ribavirin is much 
higher than that one would expect from the registration 
trial of peginterferon vs. non-peginterferon and ribavi-
rin (8). One would also have to wonder what potential 
role statin agents would have in the upcoming era of 
protease inhibitors that promise an SVR of 60%–75% in 
combination with peginterferon and ribavirin (9, 10). 
Nevertheless, the work of Malaguarnera and colleagues 
is certainly hypothesis generating and given that the 
protease inhibitors are specific for genotype 1 patients, 
statin agents, that appear to be non-toxic in HCV patients, 
may have an adjuvant role in non-genotype 1 patients for 
whom no direct acting antiviral agents (DAA) are on the 
horizon. Considering that the previously mentioned in 
vitro study suggests a role in enhancing the effect of pro-
tease and polymerase inhibitors (3), it is conceivable that 
adding a statin to the triple combination of protease/
polymerase inhibitor, peginterferon and ribavirin may 
improve on the impressive SVRs of these DAA medica-
tions. Clearly, more clinical trials are needed with these 
agents.
References
1.  Wiesinger HA, Shah J, White A, Yoshida EM, Frohlich J, Sirrs S, et 
al. Liver biochemistry abnormalities in a quaternary care lipid 
clinic database. Ann Hepatol. 2008;7(1):63-6.
2.  Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N. Different 
anti-HCV profiles of statins and their potential for combination 
therapy with interferon. Hepatology. 2006;44(1):117-25.
3.  Delang L, Paeshuyse J, Vliegen I, Leyssen P, Obeid S, Durantel D, 
et al. Statins potentiate the in vitro anti-hepatitis C virus activ-
ity of selective hepatitis C virus inhibitors and delay or prevent 
resistance development. Hepatology. 2009;50(1):6-16.
4.  Bader T, Fazili J, Madhoun M, Aston C, Hughes D, Rizvi S, et al. Flu-
vastatin inhibits hepatitis C replication in humans. Am J Gastro-
enterol. 2008;103(6):1383-9.
5.  Milazzo L, Meroni L, Galazzi M, Cesari M, Caramma I, Mar-
chetti G, et al. Does fluvastatin favour HCV replication in vivo? 
A pilot study on HIV–HCV coinfected patients. J Viral Hepat. 
2009;16(7):479-84.
6.  Milazzo L, Caramma I, Mazzali C, Cesari M, Olivetti M, Galli M, et 
al. Fluvastatin as an adjuvant to pegylated interferon and riba-
virin in HIV/hepatitis C virus genotype 1 co-infected patients: an 
open-label randomized controlled study. J Antimicrob Chemother. 
2010;65(4):735-40.
7.  Sezaki H, Suzuki F, Akuta N, Yatsuji H, Hosaka T, Kobayashi M, et 
al. An open pilot study exploring the efficacy of fluvastatin, pe-
gylated interferon and ribavirin in patients with hepatitis C vi-
rus genotype 1b in high viral loads. Intervirology. 2009;52(1):43-8.
8.  Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman 
M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin 
compared with interferon alfa-2b plus ribavirin for initial 
treatment of chronic hepatitis C: a randomised trial. Lancet. 
2001;358(9286):958-65.
9.  Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et 
al. Telaprevir and peginterferon with or without ribavirin for 
chronic HCV infection. N Engl J Med. 2009;360(18):1839-50.
10. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, et 
al. Efficacy of boceprevir, an NS3 protease inhibitor, in combi-
nation with peginterferon alfa-2b and ribavirin in treatment-
naive patients with genotype 1 hepatitis C infection (SPRINT-1): 
an open-label, randomised, multicentre phase 2 trial. Lancet. 
2010;376(9742):705-16.